Melosus 1.5 mg/ml is an analgesic and anti-inflammatory veterinary medicinal product for dogs. Melosus 1.5 mg/ml is one of the veterinary medicinal products that can only be obtained from a veterinarian or from a pharmacy on prescription from a veterinarian (UDA).
Melosus 1.5 mg/ml has the registration number:
| The Netherlands: | REG NL 106874 |
| Belgium: | EU/2/10/116/005 (10 ml) |
| EU/2/10/116/001 (25 ml) | |
| EU/2/10/116/002 (50 ml) | |
| EU/2/10/116/003 (125 ml) |
Melosus 1.5 mg/ml is an oral suspension and should be mixed with food or administered directly into the mouth.
Initial treatment is a single oral dose of 0.2 mg meloxicam per kg body weight on the first day. Daily treatment should be continued at an interval of 24 hours with a maintenance oral dose of 0.1 mg meloxicam per kg body weight, once daily.
The longer treatment duration, after a clinical effect is observed (after ≥ 4 days), the dose of Melosus can be adjusted to the lowest effective individual dose. It should be borne in mind that the degree of pain and inflammation in chronic musculoskeletal disorders can vary over time.
Active ingredient: Meloxicam 1.5mg/ml
Excipient: Sodium benzoate 1.75 mg/ml
Melosus 1.5 mg/ml is available in 10 ml, 25 ml and 125 ml bottles.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have been reported occasionally. In very rare cases, bloody diarrhoea, vomiting blood, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects usually occur within the first week of treatment and in most cases are transient and disappear after treatment is discontinued, but in very rare cases can be serious or fatal. If side effects occur, treatment should be discontinued.
The frequency of side effects is defined as follows:
